A mixed hemadsorption assay for detection of cell surface binding anti-tumor antibodies in human sera.
A practical mixed hemadsorption assay (MHA) was developed for the detection of cell surface binding anti-tumor antigen antibodies (anti-TA Ab) in the human sera. The assay was compared to enzyme-linked immunosorbent assay (ELISA) and dot ELISA in the detection of the antibodies developed against GA733-2 antigen. SW1116 cell line and recombinant GA733-2E protein were used as targets in the MHA and solid phase immunoassays (SPIA), respectively. Sera were obtained from healthy donors and vaccinated-colon carcinoma patients. The sensitivity level of the MHA was very high for detection of anti-TA Ab in sera.
Akis
Nese
N
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA. akis@mail.med.upenn.edu
Andl
Claudia
C
Zhou
Dawei
D
D000912:Antibodies, Neoplasm / Q000097:blood*; D000937:Antigen-Antibody Reactions; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines / Q000627:therapeutic use; D002462:Cell Membrane / Q000276:immunology; D003110:Colonic Neoplasms / Q000276:immunology / Q000628:therapy; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes; D006382:Hemadsorption; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D066298:In Vitro Techniques
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes